TKNO Q4 2021 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M-0.5% YoY

Gross Profit

$5M49.2% margin

Operating Income

-$5M-47.2% margin

Net Income

-$4M-36.1% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+7.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$10M

Stock-Based Comp.

$624,000

Balance Sheet

Total Assets

$167M

Total Liabilities

$23M

Stockholders' Equity

$143M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$10M	-0.5%
Gross Profit	$5M	$6M	-10.6%
Operating Income	-$5M	$795,000	-699.6%
Net Income	-$4M	$577,000	-732.1%

Revenue Segments

Lab Essentials

$7M67%

Clinical Solutions

$2M24%

Sample Transport

$495,0005%

Other Product

$432,0004%

Geographic Segments

U S

$10M98%

Non Us

$192,0002%